In this interview at ESMO 2018, Dr Yungan Tao speaks about the GORTEC 2004-01 randomised phase III trial which looked at 70 Gy/35 F with conventional radiotherapy versus 75 Gy/35 F with intensity-modulated radiotherapy. Dr Tao explains the results and limitations of the study and how this information adds to the body of evidence to support the use of intensity-modulated radiotherapy for locally advanced head and neck squamous cell carcinomas.
1. What is intensity-modulated radiotherapy (IMRT) and what are its advantages compared with conventional radiotherapy? (0:11)
2. What was the rationale for investigating dose escalation of radiotherapy when administered with cisplatin? (0:46)
3. What were the findings of this study? (1:26)
4. What were the limitations of this study? (2:53)
5. How do you expect the role of IMRT to evolve in the future? (3:43)
Speaker disclosures: Yungan Tao has nothing to disclose in relation to this interview.
Filmed at the European Society for Medical Oncology (ESMO) 2018 Congress, Munich, Germany, 19–23 October 2018.
Share this Video
Related Videos In Head and Neck Cancer
Ian Chau, ASCO 2021: First Results of the Phase III CheckMate 648 Trial
Dr Ian Chau (Royal Marsden Hospital, London, UK) joins us at ASCO 2021 to discuss the pivotal first results of the global phase III CheckMate 648 trial, which revealed first-line nivolumab regimens improve survival in esophageal squamous cell carcinoma. The abstract (LBA4001) ‘Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line […]
Jean Bourhis, ESMO 2019 – Debio 1143 in head and neck cancer
We joined Jean Bourhis at ESMO 2019 to learn a little more about the oral antagonist of inhibitor of apoptosis proteins (IAPs), Debio 1143, which is thought to act as a chemo-radio-sensitizer to enhance treatment efficacy. Questions 1. Please outline the current burden of head and neck cancer? (00:06) 2. Debio 1143 is currently under […]
Mike Gibson, ASCO 2019 – KEYNOTE-062 and KEYNOTE-48 trial data
Editorial Board member, Mike Gibson, reviews data presented at the ASCO 2019 annual meeting around the immune checkpoint inhibitor, pembrolizumab, in the treatment of head and neck cancers. This includes a discussion around KEYNOTE-062 (NCT02494583) and KEYNOTE-48 (NCT02358031) data, the factors that influence the choice of pembrolizumab monotherapy vs pembrolizumab plus chemotherapy and the role […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!